SI
EW icon

Sava Infond’s Edwards Lifesciences EW Stock Holding History

Sava Infond’s Portfolio EW Stock Details EW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$348K Hold
3,850
– – 0.02% 159
2026
Q1 		$308K Hold
3,850
– – 0.04% 167
2025
Q4 		$328K Hold
3,850
– – 0.04% 146
2025
Q3 		$299K Sell
3,850
-1,150
-23% -$89.9K 0.04% 147
2025
Q2 		$391K Hold
5,000
– – 0.06% 131
2025
Q1 		$362K Hold
5,000
– – 0.07% 131
2024
Q4 		$370K Buy
+5,000
New +$350K 0.07% 134

Other funds holding EW

Ninety One (UK)
Ninety One (UK) London, United Kingdom $44.7B AUM 17.24% 1-Year Est. Return
WT
Wellcome Trust London, United Kingdom $9.01B AUM 12.05% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
BHIA
Birch Hill Investment Advisors Boston, Massachusetts $2.47B AUM 20.95% 1-Year Est. Return
NONA
Ninety One North America New York $2.13B AUM 9.16% 1-Year Est. Return
Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return
SIM
Seilern Investment Management London, United Kingdom $794M AUM 6.63% 1-Year Est. Return
OIAM
OFI Invest Asset Management Paris, France $10B AUM 48.47% 1-Year Est. Return
FFM
Fisher Funds Management Auckland, New Zealand $3.52B AUM 17.59% 1-Year Est. Return

Sava Infond's EW Position: Q2 2026 in Review

Sava Infond held its Edwards Lifesciences (EW) position steady in Q2 2026 at 3,850 shares worth $348K. The position accounts for 0.02% of the portfolio, ranked #159.

Sava Infond first reported a position in EW in Q4 2024 and has held it in 7 quarters since. The position peaked at $391K in Q2 2025. 269 funds tracked by Wall St. Rank hold EW as of Q2 2026.

  • Sava Infond held 3,850 shares of Edwards Lifesciences worth $348K as of Q2 2026.
  • Sava Infond left its Edwards Lifesciences share count unchanged in Q2 2026.
  • Edwards Lifesciences made up 0.02% of Sava Infond's portfolio in Q2 2026, its #159 holding.
  • Sava Infond first reported a position in Edwards Lifesciences in Q4 2024 and has held it in 7 quarters since.
  • Sava Infond's Edwards Lifesciences position peaked at $391K in Q2 2025.
  • 269 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2026.

Based on Sava Infond's 13F filing for Q2 2026, filed 16 Jul 2026.